Financial reports
ARS
2023 FY
Annual report to shareholders
11 Apr 24
10-K
2023 FY
Annual report
27 Feb 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
1 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
13 Apr 23
10-K
2022 FY
Annual report
21 Feb 23
10-Q
2022 Q3
Quarterly report
1 Nov 22
10-Q
2022 Q2
Quarterly report
2 Aug 22
10-Q
2022 Q1
Quarterly report
3 May 22
Current reports
8-K
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
8-K
Esperion Announces Proposed Public Offering of Common Stock
22 Jan 24
8-K
Regulation FD Disclosure
18 Jan 24
8-K
Results of Operations and Financial Condition
11 Jan 24
8-K
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
3 Jan 24
8-K
Esperion Reports Third Quarter 2023 Financial Results
7 Nov 23
8-K
Esperion Reports Second Quarter 2023 Financial Results
1 Aug 23
8-K
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
26 Jun 23
8-K
Departure of Directors or Certain Officers
15 Jun 23
8-K
Esperion Reports First Quarter 2023 Financial Results
9 May 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
22 Jan 24
424B5
Prospectus supplement for primary offering
18 Jan 24
S-8
Registration of securities for employees
24 Aug 23
S-8
Registration of securities for employees
1 Aug 23
424B3
Prospectus supplement
22 Mar 23
424B5
Prospectus supplement for primary offering
21 Mar 23
424B5
Prospectus supplement for primary offering
21 Feb 23
S-8
Registration of securities for employees
26 May 22
S-3
Shelf registration
14 Apr 22
S-8
Registration of securities for employees
22 Feb 22
Proxies
DEF 14A
Definitive proxy
11 Apr 24
DEFA14A
Additional proxy soliciting materials
25 May 23
DEF 14A
Definitive proxy
13 Apr 23
PRE 14A
Preliminary proxy
3 Apr 23
DEF 14A
Definitive proxy
18 Aug 22
PRE 14A
Preliminary proxy
8 Aug 22
DEF 14A
Definitive proxy
14 Apr 22
PRE 14A
Preliminary proxy
4 Apr 22
DEF 14A
Definitive proxy
15 Apr 21
DEF 14A
Definitive proxy
16 Apr 20
Other
EFFECT
Notice of effectiveness
27 Apr 22
CORRESP
Correspondence with SEC
22 Apr 22
UPLOAD
Letter from SEC
22 Apr 22
CT ORDER
Confidential treatment order
19 Mar 19
EFFECT
Notice of effectiveness
19 Jan 16
UPLOAD
Letter from SEC
14 Jan 16
CORRESP
Correspondence with SEC
14 Jan 16
EFFECT
Notice of effectiveness
31 Dec 14
EFFECT
Notice of effectiveness
9 Jul 14
CT ORDER
Confidential treatment order
25 Jun 13
Ownership
4
Eric Warren
15 Mar 24
4
Joanne M. Foody
15 Mar 24
4
Benjamin Looker
15 Mar 24
4
Benjamin Halladay
15 Mar 24
4
Sheldon L. Koenig
15 Mar 24
SC 13G/A
CVI Investments, Inc.
14 Feb 24
SC 13G/A
Two Seas Capital LP
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24